BCS Wealth Management Boosts Position in Merck & Co., Inc. $MRK

Key Points

• BCS Wealth Management boosted its Merck stake by 103.0% in Q4, buying an additional 16,212 shares to hold 31,956 shares worth about $3.36 million per its SEC filing.
• Major near‑term catalysts include an FDA Priority Review for ifinatamab deruxtecan (a potential first‑in‑class ADC that could lift oncology revenue) and UBS raising its MRK price target to $145, with a MarketBeat consensus rating of "Moderate Buy" and target ~$128.47.
• Fundamentals: Merck beat Q results and set FY2026 EPS guidance of $5.00–$5.15, has a ~$296 billion market cap and a 2.8% dividend yield, but insiders have sold ~320,176 shares (~$38.3M) in the past 90 days.

BCS Wealth Management increased its stake in Merck & Co., Inc. (NYSE:MRK - Free Report) by 103.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 31,956 shares of the company's stock after buying an additional 16,212 shares during the period. BCS Wealth Management's holdings in Merck & Co., Inc. were worth $3,363,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Darwin Wealth Management LLC increased its stake in Merck & Co., Inc. by 237.4% in the 3rd quarter. Darwin Wealth Management LLC now owns 307 shares of the company's stock worth $26,000 after buying an additional 216 shares during the period. Barnes Dennig Private Wealth Management LLC increased its position in Merck & Co., Inc. by 302.3% during the 3rd quarter. Barnes Dennig Private Wealth Management LLC now owns 354 shares of the company's stock valued at $30,000 after purchasing an additional 266 shares during the period. United Financial Planning Group LLC purchased a new position in Merck & Co., Inc. during the 3rd quarter valued at about $31,000. Evolution Wealth Management Inc. purchased a new position in Merck & Co., Inc. during the 2nd quarter valued at about $31,000. Finally, Wealth Watch Advisors INC purchased a new position in Merck & Co., Inc. during the 3rd quarter valued at about $34,000. Hedge funds and other institutional investors own 76.07% of the company's stock.

Key Stories Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: FDA granted Priority Review to Merck and Daiichi Sankyo’s BLA for ifinatamab deruxtecan for previously treated extensive‑stage small cell lung cancer — if approved this could be a first‑in‑class B7‑H3 antibody‑drug conjugate with meaningful upside to oncology revenue. Article
• Positive Sentiment: UBS raised its price target on MRK from $130 to $145 and maintained a Buy rating, signaling analyst confidence in Merck’s growth trajectory and providing a potential catalyst for upside. Article
• Neutral Sentiment: Industry context — large pharma shifting to smaller, disciplined deals may leave room for strategic partnerships and targeted M&A that could benefit Merck or its competitors, but no direct near‑term impact is specified. Article
• Neutral Sentiment: Sector moves: positive clinical readouts at peers (e.g., Revolution Medicines) are lifting biotech sentiment broadly — this can shift investor flows within healthcare but does not directly change Merck’s fundamentals. Article
• Neutral Sentiment: Investor commentary pieces highlight profitability as an important factor for long‑term holders; Merck’s margins and guidance remain points investors watch but are not new catalysts. Article
• Negative Sentiment: Reputational and policy risk: reporting on how Merck built a broad patent “wall” around Keytruda and the high U.S. costs underscores political, regulatory and payer scrutiny that could pressure pricing and future revenue. Article
• Negative Sentiment: Near‑term selling pressure noted in recent market reports — short‑term stock weakness has appeared even as company news flows positive, suggesting traders are balancing the FDA news with broader market and sector dynamics. Article

Wall Street Analyst Weigh In

A number of research analysts have commented on the stock. Royal Bank Of Canada reissued an "outperform" rating and set a $142.00 target price on shares of Merck & Co., Inc. in a research report on Monday, March 30th. Wall Street Zen raised shares of Merck & Co., Inc. from a "hold" rating to a "buy" rating in a research report on Saturday, March 28th. TD Cowen raised their target price on shares of Merck & Co., Inc. from $100.00 to $120.00 and gave the company a "hold" rating in a research report on Tuesday, January 20th. Cantor Fitzgerald raised their target price on shares of Merck & Co., Inc. from $116.00 to $120.00 and gave the company a "neutral" rating in a research report on Wednesday, February 4th. Finally, Zacks Research raised shares of Merck & Co., Inc. from a "strong sell" rating to a "hold" rating in a research report on Tuesday, March 17th. One research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and seven have given a Hold rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $128.47.

Merck & Co., Inc. Stock Down 0.2%

Shares of Merck & Co., Inc. stock opened at $119.94 on Wednesday. The firm's 50 day moving average price is $119.27 and its 200-day moving average price is $105.42. The company has a quick ratio of 1.30, a current ratio of 1.54 and a debt-to-equity ratio of 0.89. Merck & Co., Inc. has a 52-week low of $73.31 and a 52-week high of $125.14. The company has a market cap of $296.24 billion, a P/E ratio of 16.48, a PEG ratio of 2.42 and a beta of 0.26.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last issued its quarterly earnings data on Tuesday, February 3rd. The company reported $2.04 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.01 by $0.03. Merck & Co., Inc. had a net margin of 28.08% and a return on equity of 44.57%. The firm had revenue of $16.40 billion for the quarter, compared to the consensus estimate of $16.19 billion. During the same quarter in the previous year, the firm earned $1.72 EPS. The company's quarterly revenue was up 5.0% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. On average, sell-side analysts predict that Merck & Co., Inc. will post 9.01 EPS for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, April 7th. Stockholders of record on Monday, March 16th were given a $0.85 dividend. The ex-dividend date of this dividend was Monday, March 16th. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.8%. Merck & Co., Inc.'s payout ratio is presently 46.70%.

Insider Buying and Selling

In related news, EVP David Michael Williams sold 5,000 shares of Merck & Co., Inc. stock in a transaction that occurred on Friday, February 6th. The shares were sold at an average price of $121.91, for a total value of $609,550.00. Following the completion of the sale, the executive vice president directly owned 30,838 shares in the company, valued at $3,759,460.58. This trade represents a 13.95% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Johannes Jacobus Oosthuizen sold 15,000 shares of Merck & Co., Inc. stock in a transaction that occurred on Friday, February 6th. The stock was sold at an average price of $121.87, for a total transaction of $1,828,050.00. Following the completion of the sale, the insider owned 21,197 shares of the company's stock, valued at $2,583,278.39. This trade represents a 41.44% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 320,176 shares of company stock worth $38,281,735 over the last ninety days. Company insiders own 0.09% of the company's stock.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.